Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 6/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314472 | 0.71 | GBA1 (0.59) | GBA1CHRNB2CHRNA4LTA4H | |
| SCHEMBL595753 | 0.69 | HTR1B (1.00) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| Iodide SCHEMBL30481083 | 0.68 | HTR1B (0.96) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL1109801 | 0.68 | HTR1B (1.00) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL10921722 | 0.68 | HTR1B (0.96) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL23067924 | 0.67 | HTR1B (0.78) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL4316558 | 0.67 | LTA4H (0.47) | CHRNB2CHRNA4LTA4H | |
| SCHEMBL6849557 | 0.66 | HTR1B (0.88) | HTR1BHTR1DL3MBTL1LTA4H | |
| SCHEMBL4318658 | 0.66 | KCNA3 (0.48) | HTR1BHTR1DL3MBTL1LTA4H | |
| SCHEMBL6850933 | 0.65 | HTR1B (0.85) | HTR1BHTR1DL3MBTL1LTA4HSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | HTR1B 8/4885HTR1D 11/4885GBA1 713/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | HTR1B 8/4885HTR1D 12/4885GBA1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.